Currently, the limited number of antifungals available for treating fungal infections, the increased multiresistance, and the adverse effects are the major obstacles for fungal infection therapy. Additionally, the recent emergence of opportunistic fungus infections reinforced the requirement for discovering novel antifungal agents. Herein we reviewed the main topics about fungi and its related infections, the antifungals available, their mechanism of action and resistance profile. In this work, we pointed fungi as a biotechnological target for finding new options in alternative sources such as marine products with new mechanisms of action to allow treating these dangerous infections.
INTRODUCTION
In the early twentieth century, bacterial epidemics were a major cause of mortality worldwide. In contrast, fungal infections were hardly taken into consideration. However, since the 1960s, when the use of antibiotic therapies has been established, a drastic increase of fungal infections was observed. Now, emerging fungal pathogens have been described causing severe infections, which include yeasts as azole-resistant Candida albicans and non-albicans species, Trichosporon species and filamentous fungi such as species of the genus Fusarium and of the class Zygomycetes, and some representatives of the dematiaceous molds. Literature also reported the medical importance of endemic dimorphic fungi such as Penicillium marneffei, Coccidioides immitis, Paracoccidioides brasiliensis (Marques, 2012) , and Histoplasma capsulatum. Therefore, fungal infections are seen as an important threat to global health that needs to get proper attention (Vandeputte et al., 2012; Gauthier and Keller, 2013) . For that purpose, molecules with a new mechanism of action and able to escape from the current fungi mechanism of resistance against antifungals are of interest.
The sea is a reservoir of a variety of organisms (bacteria, microalgae, seaweeds, invertebrate, and vertebrate animals), which are source of novel and bioactive molecules (Devi et al., 2011) (Figure 1) . Marine substances presented antifungal activity against pathogenic fungi and were isolated from sea cucumber (Kumar et al., 2007) , marine sponges (Piao et al., 2013) , seaweeds (Guedes et al., 2012) , microalgae (Kumar et al., 2013) , bacteria (Petatán-Sagahón et al., 2011) , mollusks and echinoderm (Umayaparvathi et al., 2012) , and fishes (Hellio et al., 2012) , namely, in all marine phyla (Figure 1) . Unfortunately, many studies were performed with extracts of marine organisms, without the isolation of the molecules responsible for activity against fungi.
Some important reviews on biological activities of marine products have demonstrated that the antifungal activity is one of the least investigated (Mayer and Lehmann, 2000; Hamann, 2002, 2004; Mayer and Hamannm, 2005; Mayer et al., 2007 Mayer et al., , 2009 Mayer et al., , 2011 Mayer et al., , 2013 .
In this work, our purpose is to briefly review and discuss the most important fungal infections and antifungals used in the treatment and new possibilities focused on the biotechnological marine products to contribute to the treatment of these microorganism infections that compromises human health. For that purpose, we used the keywords: marine products, fungal infections, antifungals, treatment, biotechnological products in the MEDLINE, PubMed, Embase, and Cochrane databases. FIGURE 1 | Natural products from marine organisms with significant activity against fungal strains of health and economic relevance. They can be found in marine-derived bacteria (A-Gageosatins C, a linear lipopeptide), fungi (B-Fusarielin E, a fusaricidin derivative), dinoflagellates (C-Goniodomin A, a polyether macrolide compound), red alga (D-Aldehyde derivative (E)-2-{(E) tridec-2-en-2-yl} heptadec-2-enal), sponge (E-Curcuphenol and Curcudiol), sea cucumbers (F-Holothurin B, a triterpenic glycoside), macroalga (G-Cycloartan-3,23,29-triol 3,29-disodium sulfate; a sulfate-conjugated Triterpenoid) and fungal strains within other species (H-diketopiperazine derivative produced by fungal M-3 strains within phylum Ascomycota, isolated from marine red algae Porphyra yezoensis) among others.
FUNGUS: OVERALL LOOK IN THE MAIN TOPIC
Most fungi do not cause problems in healthy individuals, but they can cause diseases in immunocompromised individuals. The most common opportunistic infections are caused by C. albicans and Aspergillus spp. In the recent years other fungi emerged as important infections agents, including yeast species such as non-albicans Candida species, Cryptococcus sp., Trichosporon spp., and Rhodotorula spp. and filamentous fungi such as Fusarium spp., Rhizopus spp., Rhizomucor spp., and phaeohyphomycosis agents (Sun et al., 2012; Juyal et al., 2013; Kim et al., 2013; Muhammed et al., 2013; Jaın et al., 2014; Schieffelin et al., 2014) .
Opportunistic mycoses have increased in the last decades, especially since 1980, due to the increase of immunocompromised patients. The predisposing factors for fungal infections include neutropenia, transplant (bone marrow or solid organ), diabetics, malignancies, malnutrition, hematological diseases and HIV. An important and major risk factor for fungal infections is the use of broad spectrum antibiotics that reduces the number of bacteria from microbiota and allows fungal growth leading to opportunistic infections. The use of devices (e.g., central venous catheters) that breaks the host-defense barriers also allows access of these agents. Thus, the use of invasive procedures and aggressive treatment (e.g., intensive care units) not only increased the survival of patients with life threatening diseases but also the number of people at risk of fungal infections (Bouza and Munoz, 2008) . Finally, changes in antineoplasic chemotherapy and radiotherapy have caused profound immunosuppression and consequently an increase in the occurrence of fungal infections. These risk factors have changed the spectrum of pathogens that cause systemic infection, in favor of multiresistant fungi that severely restrict the treatment options (Harris, 2002; Richardson, 2005; Ostrosky-Zeichner et al., 2010) .
LIFE-THREATENING FUNGAL INFECTIONS
Candida albicans is the major fungal pathogen of clinical importance causing high mortality in populations at risk, especially in immunocompromised patients, neutropenia, antibiotic use and prolonged periods in the intensive care unit predispose individuals to invasive candidiasis (Calderone and Fonzi, 2001; Wisplinghoff, 2004; Cheng et al., 2012) . This microorganism is usually a commensal of the oral cavity and gastrointestinal tract of healthy humans, but can cause serious disease (Diaz et al., 2012) .
Candida species are classified as the fourth leading cause of bloodstream infections in hospitals, causing a high mortality (35-45%) according to epidemiological studies (Wisplinghoff, 2004; Drgona et al., 2014) . In addition, non-albicans Candida species are now also associated with pertinent infections such as C. glabrata, C. krusei, C. parapsilosis and C. tropicalis, C. dubliniensis, have also emerged as causative agents of infections (Jordán et al., 2014) . The high prevalence of non-albicans species in disease might also be a consequence of their inherently higher level of resistance to certain antifungal drugs (Silva et al., 2012) .
The genus Aspergillus has about 180 species and some of them are highlighted by their clinical importance in causing human diseases (Mabey et al., 2004) . These microorganisms are opportunistic pathogens and cause infection in severely debilitated individual. Inhalation of spores is the most common route of transmission and several reports described it as an agent of secondary infection in patients with debilitating diseases such as carcinoma, tuberculosis, and lesions of subcutaneous tissues, skin or cornea, neutropenic patients or in prolonged treatment with antibiotics and corticosteroids (Zmeili and Soubani, 2007) .
Aspergillus can also invade the human system through the respiratory tract, severely damaged skin, trauma or surgical wounds, corneal, ear or significantly affected organ. Usually the infection is the initial process, which can be localized or spread, producing a widespread disease with involvement of more than one organ (Kousha et al., 2011) . Among Aspergillus species, Aspergillus fumigatus represents 70% of clinical isolates of medical importance, whereas Aspergillus flavus, Aspergillus niger and Aspergillus terreus represent 15%, 7%, and 5% respectively (Ascioglu et al., 2002) .
Cryptococcosis is an opportunistic infection caused by fungi belonging to the genus Cryptococcus sp. There are over 30 different species, but Cryptococcus neoformans and Cryptococcus gattii are responsible for almost all cases of cryptococcosis in humans and animals. Infections can occur in both immunocompromised and immunocompetent hosts (Bovers et al., 2008) . Cryptococcal meningitis is the main clinical manifestation and is associated with high mortality (Quian et al., 2012) .
Fusarium spp. are important infectious filamentous fungi, it is particularly important among immunocompromised and neutropenic patients and is typically invasive and disseminated. Infection occurs mainly through inhalation of airborne conidia or via breaks in the skin due to trauma and/or burns (Muhammed et al., 2011) . Twelve species were associated with infection; Fusarium solani was the most frequent (∼50% of cases), followed by Fusarium oxysporum (∼20%) and Fusarium verticillioidis and Fusarium moniliforme (∼10% each) (Nucci et al., 2013) .
The mycoses encompassed in the hyalohyphomycosis group are very heterogeneous, with only the presence of hyaline hyphae in tissues as a common characteristic. The number of organisms implicated in hyalohyphomycosis is increasing and the most clinically important species belong to the genera Fusarium, Scedosporium, Acremonium, Scopulariopsis, Purpureocillium, and Paecilomyces (Tortorano et al., 2014) .
Zygomycosis, also known as mucormycosis, has emerged as an increasingly important pathogen during the past decade. Mucormycosis is a life-threatening invasive fungal infection that arises among immunocompromised patients, and the rhinoorbito-cerebral presentation is the most common clinical form of the disease (Teixeira et al., 2013) . As failure rates are elevated with commercial antifungals, new treatment options are needed (Waness et al., 2009 ).
CURRENT ANTIFUNGALS BIOLOGICAL FEATURES
Currently the treatment of fungal infections is still complex, as fungi are eukaryotic organisms with similar structure and metabolism with the host cell. This feature is often responsible for the toxicity of these compounds (Sathiamoorthy et al., 2006) .
Despite extensive research devoted to the development of new therapeutic strategies, there are only a limited number of drugs available for the treatment of invasive fungal infections (Figure 2 and Table 1 ). In fact, only four molecular classes that target three different fungal metabolic pathways are commonly used in clinical practice to treat systemic fungal infections such as fluoropyrimidine analogs, polyenes, azoles and the echinocandins (Vandeputte et al., 2012) (Table 1) .
5-Fluoropyrimidine
5-fluorocytosine (5-FC) is a fluorinated derivative of cytosine. It is a prodrug and its fungistatic activity is dependent on its conversion to 5-fluorouracil (5-FU). 5-FC rapidly enters into the fungus cytoplasm through specific transporters such as cytosine permeases and pyrimidine transporters before being converted to 5-FU by the cytosine deaminase (Hope et al., 2004) . Resistance may emerge during therapy due to the decrease of the concentration of the enzyme involved in the conversion of 5-flucytosine (1) to 5FdUMP, or to the increase of cytosine synthesis (Vermes et al., 2000) (Figure 2 and Table 1 ).
Polyenes
More than 200 molecules that belong to this chemical class present an antifungal activity. However, only three are used in clinical medicine. Amphotericin is a polienic molecule that may be fungicidal or fungistatic depending on the dose used (Ellis, 2002) . It remains for over 40 years as the first-line drug in the treatment of invasive fungal infections due to their broad spectrum of activity and low occurrence of innate or acquired resistance (Ellis, 2002; Adler-Moore and Proffitt, 2008) . Meanwhile Natamycin and nystatin (2) are polienic drugs effective against fungi of the genus Cryptococcus, Candida, Aspergillus and Fusarium (Zotchev, 2003) (Figure 2 and Table 1 ).
Azoles
The antifungal azoles include two classes: imidazoles (first generation) and triazoles (Second generation) (Zonios and Bennet, 2008) (Figure 2 and Table 1 ). The therapeutic target of azoles is the lanosterol 14-α-demethylase (CYP51) and its heme group (Figure 3) . The inhibition of CYP51 leads to depletion of ergosterol, the main steroid present in fungal membrane, and accumulation of squalene or other toxic intermediaries in the cell, changing the membrane permeability and the fungal viability (Ascioglu et al., 2002; Bovers et al., 2008; Strushkevich et al., 2010) .
All triazoles show oral activity and voriconazole (3) (Figure 2 ) may be administered also intravenously (Tkackz and Didomenico, 2001) . New triazoles (e.g., voriconazole, posaconazole, and ravuconazole) have greater potency and broader spectrum of action. Among the three azole drugs, voriconazole was approved for clinical use by the FDA in the United States as well as posaconazole in oral suspension form for the prophylactic use including of invasive aspergillosis in immune compromised patients. Itraconazole also presents in vitro activity against amphotericin B resistant Aspergillus species and other filamentous fungi with a safety profile (Scott and Simpson, 2007) .
Echinocandins
The echinocandins are synthetically modified lipopeptides naturally produced by some species of fungi such as Aspergillus rugulovalvus (caspofungin B), Zalerion arboricola (pneumocandin) and Papularias phaerosperma (papulacandin) (Denning, 2002) .
Some of these antifungals (e.g., Caspofungin) act on enzymes that synthesize the fungal cell wall, which is composed of several polysaccharides such as beta (1,3)-glucan, beta (1,6)-glucan, and chitin carbohydrates [e.g., Beta-(1,3) -glucan synthase]. This inhibition leads to osmotic imbalance and the microorganism unavailability (White et al., 1998) .
Echinocandins are poorly absorbed in the gastrointestinal tract because of their high molecular weight and are used only intravenously. Their pharmacological properties are one of the causes for the FDA approval, also including their low toxicity (very rare side effects have been reported) and slowly metabolization. A daily injection is sufficient and in contrast to other antifungal agents, interactions between echinocandins and other drugs are rare (Denning, 2002) . Combination therapy between Amphotericin B and echinocandins often leads to a synergistic or at least an additive effect.
MECHANISM OF ANTIFUNGALS RESISTANCE
The incidence of fungal infections has increased dramatically over the past three decades followed by the increase of the fungi resistance (Pfaller et al., 2011) . These microorganisms develop resistance mechanisms against the fungistatic or fungicidal effects of the antifungal agents. The three main mechanisms are: (a) reduction of drug accumulation in the fungal cell, (b) decrease of the target affinity for the drug, and (c) change in the metabolism that prevents and/or affects drug's efficiency (Devi et al., 2011) .
Currently the antifungal agents available are insufficient to fully treat the infections in patient populations. Therefore, the The group composed of caspofungin, micafungin and anidulofungin (4) (Figure 2 ) presents antifungal spectrum restricted to species as Candida (e.g., fungicides) and Aspergillus (e.g., fungistatics) Denning, 2002 Denning, , 2003 development of new antifungal agents has been continuously required in clinical therapy (Tang et al., 2010) . At present, the major problem in the treatment of these infections and related diseases is the increasing appearance of multiresistant strains (MDR). This issue may be a consequence of errors in the drug disposal and the use of few and old medicines available in the market which failure in healing the disease. Factors as those related to the infection site, host immune response, strain virulence, drug pharmacokinetics and minimum inhibitory concentration (MIC) of the prescribed drug are also involved in fungi resistance emergence (Shapiro et al., 2011) . Mechanisms of resistance against antifungal may be associated with the entry of the molecule into the cell, its efflux, inactivation or degradation and activity on target cell (White et al., 1998) . Azoles antifungals are commonly used, and consequently, there are reports about their antifungal mechanism, pharmacological properties, and resistance mechanisms (Vandeputte et al., 2012) . The prophylactic use of azoles (fluconazole) in neutropenic patients has an impact on the reduction of Candida related infections in this population (Lortholary and Dupont, 1997) . On the other hand, the emergence of infections caused by fluconazole-resistant Candida, such as C. glabrata and C. krusei has been observed.
The prolonged use of prophylactic fluconazole in bone marrow transplant patients was associated with a higher occurrence of filamentous fungus infections (Marr et al., 2010) . Besides, the use of new antifungal agents, for example, voriconazole (3) (Figure 2 ), was associated with increased numbers of zygomycosis in immunocompromised patients. The use of caspofungin in the treatment of C. krusei infection has also been associated with zygomycosis outbreak (Girmenia et al., 2005) .
The global expansion of resistance to antifungal agents is an evolutionary response to the indiscriminate use of therapy for several decades. Despite the existing antifungal agents for the 
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treatment, resistance has been the main and a greater challenge for scientists and pharmaceutical and biotechnology companies (Bremner et al., 2007; Kaufman, 2011) . Altogether, these results revealed the importance of the specialist to perform the prescription of an antifungal agent and the urgent need for new options of treatment, including different approaches and molecules from different origins and mechanisms of action.
BIOTECHNOLOGY AND SOME NEW OPTIONS FOR FUNGUS THERAPY AND PREVENTION

Different approaches and different alternative sources
New antifungal agents that act on other targets than the drugs currently available as well as new immunological approaches to increase host response in the treatment and/or prevention of fungal infections are promising possibilities for future therapy of fungus infection (Groll et al., 2002; Ostrosky-Zeichner et al., 2010) .
The need for discovering available drugs being able to control emerging infections and resistant strains stimulate the necessity to look for unconventional new sources of bioactive natural products. In this aspect, marine natural products could be an attractive field, (El Amraoui et al., 2014) .
Natural products have been shown to be an excellent source of novel chemical entities. The discovery of caspofungin in treating invasive aspergillosis and candidiasis and of the 1,3-β-D-glucan synthase as a target for treatment of fungal infections has begun a new era for antifungal therapy (Onishi et al., 2000; Keating and Figgitt, 2003; Walker et al., 2011) .
Literature described the isolation of antifungals from natural sources such as chryscandin, chaetiacandin, pyrrolnitrin and many other natural products are currently under investigation (Yamashita et al., 1984; Komori et al., 1985; Barrett, 2002) . Peptides isolated from several animal species have also been studied, including those from the Brazilian snake venoms (Gomes et al., 2005) such as Crotamine, a peptide from Crotalus durissus terrificus venom active against Candida spp., Trichosporon spp., and Cryptococcus neoformans. The native crotamine so as the chemically produced synthetic crotamine showed similar activity, whereas recombinant crotamine was more potent in most assays (Yamane et al., 2013) .
According to the literature, failure in therapy using the current antifungal compounds have been detected even when a specific pathogen is considered susceptible to them. This paradox highlights the need of an intact and efficient immune system to prevent invasive fungal infections and to effectively control infections (Casadevall and Pirofski, 2001; Pappas, 2004) . The availability of granulocyte infusions, administration of cytokine growth factors, the use of recombinant cytokines, antibody therapy, and vaccines are some of the recent advances in biotechnology that have been studied for application in fungal therapy and prevention, especially in immunocompromised patients (Stevens et al., 2000; Casadevall and Pirofski, 2001) .
Several studies have reported the search for new vaccines (Devi et al., 1991; Han et al., 1999; Segal, 1999; Stevens et al., 2000; Casadevall and Pirofski, 2001; Torosantucci et al., 2005; Spellberg et al., 2008; Liu and Filler, 2011; Sandini et al., 2011; Cassone and Casadevall, 2012) , particularly against cryptococcosis, histoplasmosis (Georgopapadakou and Walsh, 1996; Chaturvedi and Wormley, 2013) coccidioidomycosis, blastomycosis and candidiasis (Segal, 1999; Barnato et al., 2001; Walsh, 2002; Cassone and Casadevall, 2012) . Polysaccharide-protein conjugate vaccines were shown to be effective against Cryptococcus neoformans (Devi et al., 1991) and Candida albicans (Han et al., 1999) . Recently, a polysaccharide-protein conjugate vaccine that uses the algal glucan, laminarin has shown to be immunogenic and to induce protection in mice against aspergillosis and candidiasis (Torosantucci et al., 2005) .
Marine natural product as antifungal agent
Marine natural product bioprospecting has yielded a considerable number of drug candidates and can be used to produce several novel products that have applications in new medical technologies (Wijffels, 2008) . During the last few years the scientific community has shown a considerable interest in the study of algal extract as sources of new compounds that might lead to therapeutically useful agents, especially novel antibiotics in order to combat new diseases and drug-resistant pathogens that are becoming a significant threat to public health (Guedes et al., 2012; Xiong et al., 2013) . Marine derived have been proven to be a rich source of structurally unique and biologically active secondary metabolites with biological potential (Figure 2) . A number of new metabolites have been isolated and identified and their biological activities have been evaluated (Molinski et al., 2009) .
Extensive reviews on marine pharmacology have been described covering the varied biological activities found in these microorganisms as an anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, protozoa, antituberculosis, antiviral activities (Bhatnagar and Kim, 2010; Mayer et al., 2013) .
There is great interest in the research and investigation of the biological potential of both marine organisms and marine microorganisms as producers of new drugs including antifungics (Figures 2, 3) (Alghazeer et al., 2013) .
Cyanobacteria and Algae. The antimicrobial activity of microalgae and macroalgae has been attributed to compounds belonging to several chemical classes, including insoles, terpenes, acetogenins, phenols, fatty acids and volatile halogenated hydrocarbons (Mhadhebi et al., 2012; Alghazeer et al., 2013) (Table 2) .
Mhadhebi and coworkers evaluated 24 organic extracts obtained from six marine algae (the brown marine seaweeds, Cystoseira crinite, Cystoseira compressa, Cystoseira sedoides Dictyopteris membranaceae, and two red seaweeds Gelidium latifolium, and Halurus equisetifolius) collected from Tunisian Mediterranean coasts and discovered that algae C. crinita and C. sedoides showed an interesting result against C. albicans and C. kefyr with diameter of the inhibition zones between 23 and 44.3 mm for the chloroformic extract and ethyl acetate extract (Mhadhebi et al., 2012) .
Blue-green algae are rich sources of structurally novel and biologically active metabolites which are shown to exhibit anticancer, antimicrobial, antifungal or anti-inflammatory and other pharmacological activities. Kumar et al. (2013) observed that methanol extracts of the algae Phormidium fragile exhibited potential antifungal activity against Aspergillus flavus, Candida albicans, and Trichoderma viride (Kumar et al., 2013) .
Interestingly, the phenolic content of extracts from two brown algae Padina pavonica and Sargassum vulgare from the Lebanese coast showed antioxidant and the antifungal activities (Khaled et al., 2012) . In fact, the ethyl acetate fraction of the algae P. pavonica showed an interesting antifungal activity against Candida glabrata and C. krusei with diameter of inhibition with 16 and 14 mm respectively.
The red algae have been described as an important source of bioactive molecules. The Rhodophyta Asparagopsis taxiformis collected from the Straits of Messina (Italy) were screened for antifungal activity against Aspergillus species and showed great activity with MIC between 0.15 and 5 mg ml −1 (Genovese et al., 2013) . Specimens of the red alga Bostrychia tenella J. Agardh collected from São Paulo coast presented high activity in an antifungal assay with the phytopathogenic fungi Cladosporium cladosporioides and Cladosporium sphaerospermum (de Felício et al., 2010) .
Dinoflagellates. Polyether macrolides compounds are very common among marine dinoflagellates. Goniodomin A (5) (Murakami et al., 1988) was isolated from various marine dinoflagellates, e.g., Goniodoma pseudogoniaulax and is an antifungal polyether macrolide (Murakami et al., 1988; Mizuno et al., 1998) as well as the gambieric acids (e.g., gambieric acid B) (7) (Figure 2) (Nagai et al., 1992) .
Dinoflagellates are an important source of bioactives natural products, like amphidinols, lingshuiols and zooxanthellatoxins (Washida et al., 2006) . Amphidinols (AMs) are an important class isolated from the dinoflagellates Amphidinium klebsii that presents potent antifungal acitivity with great membranedisrupting activity (Houdai et al., 2004) , and in 2008 fourteen was estimated to have been isolated (Morsy et al., 2008) .The AMs antifungal activity is probably due to the interaction with membrane lipids that increase the permeability (Houdai et al., 2005) .
Washida and collaborators isolated two microbial polyol compounds from the cultured marine dinoflagellate Amphidinium sp.: Karatungiols A and B, and was observed for Karatungiol A antifungal activity against NBRC4407 Aspergillus niger (12 μg/disc) and antiprotozoan activity against Trichomonas foetus (1 μg/ml) (Washida et al., 2006) (Table 2) .
Marine sponges. Marine sponges are among the richest sources of interesting chemicals produced by marine organisms (Laport et al., 2009) . These organisms produce a wide variety of substances with antimicrobial activity, including terpenoids, alkaloids, nitrogenous metabolites, cyclic peptides, fatty acids, glycolipids, and macrolides (Gaspar et al., 2004; Sipkema et al., 2005) . Among the antifungal activities from marine sponges 
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Red algae Methanolic extracts C. albicans Saidani et al., 2012 recently described, we highlight the activity (±)-Curcuphenol (6) and (+)-curcudiol (Figure 2 ) isolated from marine sponges against species such as Trichophyton mentagrophytes (Gaspar et al., 2004) . A new bicyclic glycopeptide, Theonellamide G, from the Red Sea Marine Sponge Theonella swinhoei showed potent antifungal activity toward wild and amphotericin B-resistant strains of Candida albicans with IC50 of 4.49 and 2.0 μM, respectively. Beyond that, it displayed cytotoxic activity against the human colon adenocarcinoma cell line (HCT-16) with IC50 of 6.0 μM compared to 2.0 μM for positive control (Youssef et al., 2014) .
Another studies unveiled the potential of the marine products as Aurantosides, described in many studies with antifungal activity. Angawi and cols isolated four aurantosides, including a new compound Aurantoside J, from a Indonesian specimen of Theonella swinhoei and tested against C. albicans, C. parapsilosis, C. glabrata, C. tropicalis, and Fusarium solani (Angawi et al., 2011) . The results reveal that Aurantoside I exhibited a very good antifungal effect against all the tested strains, especially for Candida. Interestingly the authors suggested that the mechanism of the antifungal action of aurantoside I could be related to the mechanism of other polyene antifungal agents as nystatin ( Table 2) .
The Aurantoside K was isolated from a marine sponge belonging to the genus Melophlus sp (Kumar et al., 2012) and evaluated their antifungal activity against different fungals with clinical importance and showed great antifungal activity against amphotericin-resistant C. albicans and wild type C. albicans with the MIC at 31.25 and 1.95 μg/mL, respectively.
The Polyketides derived from marine sponges showed antifungal activity for Cryptococcus neoformans (Yu et al., 2012) . In Brazilian coasts, the antifungal profile of 21 crude extracts obtained from marine sponges was evaluated against aflatoxin-producing strains of Aspergillus flavus. Finally, Batzelladine L, isolated from the marine sponge Monanchora arbuscula and the extract of the sponge Amphimedon sp, which was shown to be enriched in halitoxins and amphitoxins showed potent antifungal activity that should be further explored (Arevabini et al., 2014) .
Marine Microorganism. Most kinds of macroorganisms such as algae, sponges and corals have extensively been investigated for their natural products content. These macroorganisms also serve as hosts for microorganisms and were recently considered as an important source of natural products.
The marine environment is a habitat for many unique microorganisms, which produce biologically active compounds to adapt to particular environmental conditions (Penesyan et al., 2010) . Marine bacteria and fungi are of considerable importance as new promising sources of a huge number of biologically active products. These marine microorganisms have proven to be an attractive source of new bioactive secondary metabolites (Yamazaki et al., 2012) .
Marine microorganisms are known to produce bioactive substances in the marine environment, predominantly protecting themselves from environmental dangers such as predation and defense mechanisms for protecting their host organism. The microorganism generally accumulate structurally unique bioactive secondary metabolites not found in terrestrial (Debbab et al., 2010) . In recent years, marine microbes have become important in the study of novel microbial products exhibiting antibacterial (Leyton et al., 2011) , antiviral (Tong et al., 2012) , antihelmintic (Dahiya and Gautam, 2011) properties. Microorganisms represent promising natural product sources having the advantage of large-scale cultivation and fermentation of the source organisms. Fungi produce a vast range of secondary metabolites and also believed to be prolific resources of natural products. Tarman et al. (2011) isolated 11 fungal strains from Indonesian marine habitats (Tarman et al., 2011) . The ethyl acetate extracts of their culture broth were tested for cytotoxic activity against a urinary bladder carcinoma cell line and for antifungal and antibacterial activities. From the 11 isolates only four strains exhibited antifungal properties against Candida maltose. The fungal strain (KT29) displayed fungicidal properties against the plant pathogenic fungus Cladosporium cucumerinum.
The chemical constituents and antifungal activity of marine sponges Haliclona baeri and Haliclona cymaeformis from the Gulf of Thailand were investigated against Candida, Aspergillus and dermatophyte strains (Wattanadilok et al., 2007) . The nortetillapyrone isolated showed some activity against C. Tropicalis (2.0 μg/ml) and good activity against C. Glabrata (62.5-31.25 μg/ml), C. dubliniensis (62.5 μg/ml) and Cryptococcus neoformans (31.25 μg/ml). In Addition, this compound exhibited significant antifungal activity against dermatophytes with the MIC values ranging from 31.25 to 1.5 μg/ml.
The diversity and antimicrobial activity of bacteria from the marine sponges Suberites carnosus and Leucosolenia sp were evaluated by Flemer and coworkers (Flemer et al., 2012) . Two hundred and thirty-seven bacteria were isolated from these macroorganisms and 69 isolates showed clear activity against at least one of the test strains studied and reveal that both sponges possess a diverse range of bioactive and potentially novel bacteria. Interestingly, the results suggest that S. carnosus isolates may be a better source of antibacterial compounds, while Leucosolenia sp. Isolates seems to be a better source of antifungal compounds.
CONCLUSIONS
Altogether, these data showed herein point to the need of further studies to find new treatment options to fight against the fungus infections and the resistant strains. As part of our general interest in the isolation and characterization of bioactive metabolites from marine organisms with potential pharmaceutical, the marine natural products emerges as a potential source of antifungal substances that should be investigated clinically besides in vitro and in vivo. Biological targets for marine products include those already detected for other antifungals such as Lanosterol 14-α-demethylase (CYP51) or new ones may be identified to overcome the current fungi resistance mechanisms, such as Ribose-5-phosphate isomerase B (Figure 3) .
